[go: up one dir, main page]

WO2002013760A3 - Methods and compositions for the repair and/or regeneration of damaged myocardium - Google Patents

Methods and compositions for the repair and/or regeneration of damaged myocardium Download PDF

Info

Publication number
WO2002013760A3
WO2002013760A3 PCT/US2001/024223 US0124223W WO0213760A3 WO 2002013760 A3 WO2002013760 A3 WO 2002013760A3 US 0124223 W US0124223 W US 0124223W WO 0213760 A3 WO0213760 A3 WO 0213760A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
regeneration
repair
damaged myocardium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024223
Other languages
French (fr)
Other versions
WO2002013760A2 (en
WO2002013760A9 (en
Inventor
Piero Anversa
Donald Orlic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Medical College
US Department of Health and Human Services
Original Assignee
New York Medical College
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College, US Department of Health and Human Services filed Critical New York Medical College
Priority to CA002423592A priority Critical patent/CA2423592A1/en
Priority to EP01961855A priority patent/EP1315510A4/en
Priority to AU2001283088A priority patent/AU2001283088A1/en
Publication of WO2002013760A2 publication Critical patent/WO2002013760A2/en
Publication of WO2002013760A3 publication Critical patent/WO2002013760A3/en
Anticipated expiration legal-status Critical
Publication of WO2002013760A9 publication Critical patent/WO2002013760A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Dental Preparations (AREA)

Abstract

Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.
PCT/US2001/024223 2000-07-31 2001-07-31 Methods and compositions for the repair and/or regeneration of damaged myocardium Ceased WO2002013760A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002423592A CA2423592A1 (en) 2000-07-31 2001-07-31 Methods and compositions for the repair and/or regeneration of damaged myocardium
EP01961855A EP1315510A4 (en) 2000-07-31 2001-07-31 METHOD AND COMPOSITIONS FOR REPAIRING AND / OR REGENERATING THE DAMAGED HEART MUSCLE
AU2001283088A AU2001283088A1 (en) 2000-07-31 2001-07-31 Methods and compositions for the repair and/or regeneration of damaged myocardium

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22190200P 2000-07-31 2000-07-31
US60/221,902 2000-07-31
US25856400P 2000-12-29 2000-12-29
US60/258,564 2000-12-29
US25880501P 2001-01-02 2001-01-02
US60/258,805 2001-01-02

Publications (3)

Publication Number Publication Date
WO2002013760A2 WO2002013760A2 (en) 2002-02-21
WO2002013760A3 true WO2002013760A3 (en) 2002-04-18
WO2002013760A9 WO2002013760A9 (en) 2003-09-04

Family

ID=27397004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024223 Ceased WO2002013760A2 (en) 2000-07-31 2001-07-31 Methods and compositions for the repair and/or regeneration of damaged myocardium

Country Status (4)

Country Link
EP (1) EP1315510A4 (en)
AU (1) AU2001283088A1 (en)
CA (1) CA2423592A1 (en)
WO (1) WO2002013760A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732199B2 (en) 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
CN1543500B (en) 2001-07-12 2014-04-09 杰龙公司 Generation of cardiomyocyte lineage cells from human pluripotent stem cells
US7527968B2 (en) 2002-07-29 2009-05-05 Robarts Research Institute Regeneration initiating cells
ITRM20030376A1 (en) 2003-07-31 2005-02-01 Univ Roma PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA.
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
KR20130099253A (en) 2005-06-22 2013-09-05 제론 코포레이션 Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
MY147516A (en) 2005-11-07 2012-12-31 Amorcyte Inc Compositions and method of vascular injury repair cross-reference to related applications
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2008011094A2 (en) * 2006-07-18 2008-01-24 Robert Sackstein Cytokine induction of selectin ligands on cells
CA2743701A1 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
CA2743698A1 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
US8241907B2 (en) 2008-01-30 2012-08-14 Geron Corporation Synthetic surfaces for culturing stem cell derived cardiomyocytes
CA2743255C (en) 2008-12-03 2014-02-18 Andrew Pecora Infarct area perfusion-improving compositions and methods of vascular injury repair
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (en) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN118490802B (en) * 2024-05-31 2025-03-18 中国人民解放军海军特色医学中心 A composition for improving exercise-induced myocardial injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5083098A (en) * 1996-10-25 1998-05-22 Icogen Corporation Use of leptin to stimulate hematopoiesis
CA2339182C (en) * 1998-07-31 2010-04-06 Genzyme Corporation Improvement of cardiac function by mesenchymal stem cell transplantation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOLANTE-CERVANTES ET AL.: "Pattern of localization of primitive hematopoietic cells in vivo using a novel mouse model", EXPERIMENTAL HEMATOLOGY, vol. 27, no. 8, August 1999 (1999-08-01), pages 1346 - 1352, XP002907061 *
ORLIC ET AL.: "Transplanted hematopoietic stem cells repair myocardial infarcts", BLOOD, vol. 96, no. 11, 16 November 2000 (2000-11-16), pages 221A, ABSTRAT NO. 943, XP002907062 *
See also references of EP1315510A4 *
YAHATA ET AL.: "Reconstitution of immune systems in RAG2 -/- mice by transfer with interleukin-12-induced splenic hematopoietic progenitor cells", IMMUNOLOGY LETTERS, vol. 62, no. 3, 1998, pages 165 - 170, XP002907060 *

Also Published As

Publication number Publication date
WO2002013760A2 (en) 2002-02-21
EP1315510A4 (en) 2005-08-03
AU2001283088A1 (en) 2002-02-25
CA2423592A1 (en) 2002-02-21
WO2002013760A9 (en) 2003-09-04
EP1315510A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
WO2002009650A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002013760A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2007100530A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
IL215423A0 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002058599A3 (en) Annulus repair systems and methods
WO2001080865A3 (en) Joint repair using mesenchymal stem cells
WO2009062143A3 (en) Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
WO2001034835A3 (en) Method for the production of biopolymers with modified properties
WO2004048593A3 (en) Methods for using riboprimers for strand displacement replication of target sequences
WO2005082056A3 (en) Reusable envelope structures and methods
WO2001083554A3 (en) Anti-inflammatory compounds and uses thereof
WO2004080175A3 (en) Scaffold for cell growth and differentiation
IL148175A0 (en) Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2002002596A3 (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
DE69824605D1 (en) IMPROVED PLANT TRANSFORMED BY AGROBACTERIES
AU2003297568A1 (en) Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
WO2005054495A3 (en) Ligand-containing micelles and uses thereof
WO2005001033A3 (en) Tolerance induction and maintenance in hematopoietic stem cell allografts
WO2005108416A3 (en) Myosin light chain kinase inhibitors and their use
WO2003084926A3 (en) Polymeric acyl derivatives of indoles
WO2003027265A3 (en) Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
WO2005089420A3 (en) Expansion of neural stem cells with lif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001283088

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001961855

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2423592

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001961855

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/29-29/29, DRAWINGS, REPLACED BY NEW PAGES 1/29-29/29; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001961855

Country of ref document: EP